Cervical Cancer

Overview
Epidemiology
Pathophysiology
Etiology and Risk Factors
Clinical Presentation
Diagnosis
Treatment
Complications
Prognosis
Prevention
Recent Research and Advances
Research Papers
Connections
Featured Videos

1. Overview

Cervical cancer is a malignancy that begins in the cells of the cervix — the lower, narrow end of the uterus that opens into the vagina. Here is the single most important fact about it, and the one that should shape how you think about everything else on this page: nearly 100% of cervical cancers are caused by a persistent infection with high-risk human papillomavirus (HPV). This is not a cancer that strikes at random. It develops slowly, over years, from a viral infection we can now both prevent and detect early. That makes cervical cancer one of the most preventable cancers that exists.

We have two powerful tools, and used together they are remarkably effective. The first is the HPV vaccine, which prevents the infections that cause the cancer in the first place. The second is screening — the Pap test and HPV test — which finds the slow-growing precancerous changes years before they could ever become cancer, when a simple office procedure can remove them. Countries that use both well, like Australia, are on track to essentially eliminate cervical cancer as a public health problem. That is an extraordinary thing to be able to say about a cancer.

If you have HPV, or have ever had an abnormal Pap result, please read on without alarm. HPV is extremely common — the overwhelming majority of sexually active people acquire it at some point, and most never know because the body clears it on its own. Having HPV is not a moral failing or a sign of anything you did wrong; it is roughly as ordinary as catching a cold. The goal of this page is to explain plainly what the virus does, what your test results actually mean, and what modern treatment looks like — with real numbers and named studies, but in language meant for you, not for a medical conference.

2. Epidemiology

Globally, cervical cancer is the fourth most common cancer in women, with roughly 660,000 new cases and about 350,000 deaths each year. The burden is profoundly unequal. Around 90% of those deaths occur in low- and middle-income countries, where vaccination and screening are scarce. In other words, where the prevention tools exist, the cancer is rare; where they don't, it remains a leading killer of women. This is one of the clearest examples in all of medicine of a disease defined less by biology than by access to care.

In the United States, widespread Pap screening since the mid-twentieth century cut deaths dramatically — by more than 70% over a few decades. Today the US sees roughly 13,000–14,000 new invasive cases and about 4,000 deaths a year. The critical point for an American reader is who gets it now. Studies of US cases consistently find that the large majority occur in women who were never screened or were under-screened — women who had no Pap or HPV test in the years before diagnosis, or who never followed up on an abnormal result. Barriers include lack of insurance, lack of a regular doctor, language and immigration concerns, and simply falling through the cracks. The lesson is hopeful and direct: the cancer is overwhelmingly preventable, and the women most at risk are usually the ones the system failed to reach, not the ones who did anything wrong.

Cervical cancer most often appears between the ages of 35 and 55, though precancerous changes are typically found a decade or more earlier through screening. It is uncommon under 20 and in well-screened older women.

3. Pathophysiology — How HPV Causes the Cancer

Understanding the disease starts with understanding the virus, and the biology is genuinely understandable if we go step by step.

Step one: a very common infection. Human papillomavirus is spread through skin-to-skin and sexual contact. There are dozens of types; about 14 are considered high-risk for cancer, and two of those — HPV-16 and HPV-18 — cause roughly 70% of all cervical cancers. Most people who are sexually active will be infected by one HPV type or another. The body's immune system usually clears these infections within one to two years, and they cause no lasting harm. This is the normal, expected outcome.

Step two: persistence. The trouble begins only when a high-risk infection does not clear and instead lingers for many years. Persistent infection — not the initial infection — is the real risk. This is why cervical cancer takes so long to develop and why there is such a wide window to catch it.

Step three: the viral proteins that disable the cell's safety brakes. Two HPV genes, called E6 and E7, make proteins that sabotage the cell's natural defenses against cancer. Healthy cells have two crucial “guardian” proteins: p53, which orders a damaged cell to stop dividing or self-destruct, and Rb (retinoblastoma protein), which holds the brake on cell division. Think of p53 as a quality inspector and Rb as a parking brake. The viral E6 protein destroys p53 (the inspector is fired) and the viral E7 protein inactivates Rb (the brake is released). With both safeguards gone, the infected cells begin to divide without restraint and accumulate genetic errors.

Step four: precancer, then cancer. Over years, these changes progress from mild abnormality to precancer (called CIN, cervical intraepithelial neoplasia, graded 1 to 3) and finally, in some women, to invasive cancer. Crucially, every step before invasion is treatable, and most precancers never become cancer at all. Screening exists precisely to interrupt this slow march — usually at the precancer stage, when removal is simple and curative.

4. Etiology and Risk Factors

The cause is HPV. But several cofactors raise the chance that an HPV infection will persist and progress rather than clear:

Persistent high-risk HPV — the necessary cause. Without it, cervical cancer essentially does not occur.
Smoking — a strong, well-established cofactor. Tobacco chemicals concentrate in cervical mucus, damage local DNA, and weaken the immune response that would otherwise clear HPV. Smokers have roughly double the risk. This is one risk factor entirely within your control.
A weakened immune system — especially HIV infection or immunosuppressive medication after an organ transplant. A healthy immune system clears most HPV; a suppressed one cannot, so infections persist and progress faster. Women with HIV need more frequent screening.
Many years of HPV exposure — longer cumulative exposure raises the odds of a persistent infection.
Long-term oral contraceptive use and multiple full-term pregnancies — modest associations in large studies; not reasons to avoid contraception, but part of the overall picture.
Never being screened or vaccinated — not a biological cause, but in practice the dominant risk factor for actually dying of this disease.

Notice what is not on this list: family history plays only a minor role, and there is nothing you ate or any single behavior that “gave you” cancer. HPV is so common that acquiring it carries no blame.

5. Clinical Presentation — Symptoms

The hardest truth about cervical cancer symptoms is this: early disease usually causes no symptoms at all. Precancer and very early cancer are silent. This is exactly why screening matters — it finds the disease before you would ever feel it. Waiting for symptoms means waiting too long.

When symptoms do appear, they typically signal that a cancer has grown enough to bleed or irritate tissue. See a clinician promptly if you have:

Bleeding after sex (post-coital bleeding) — one of the most characteristic warning signs.
Abnormal vaginal bleeding — between periods, heavier or longer periods, or any bleeding after menopause.
Unusual vaginal discharge — watery, bloody, or foul-smelling.
Pain during intercourse.

More advanced disease may cause pelvic or lower-back pain, leg swelling, difficulty or pain with urination, or blood in the urine or stool as the tumor presses on or invades nearby structures. None of these symptoms prove cancer — infections and benign conditions cause them far more often — but all of them deserve a check-up rather than a wait-and-see.

6. Diagnosis — Screening and Decoding Your Results

Cervical cancer is almost the only common cancer with an excellent, decades-proven screening test. Here is how it works in plain terms.

The Pap test versus the HPV test

A Pap test (Pap smear) collects a few cells from the cervix and looks at them under a microscope for abnormal-looking changes. A primary HPV test checks the same kind of sample for the high-risk virus itself. Because the virus is the cause, primary HPV testing is more sensitive at finding women at risk, and it is increasingly the preferred first-line test. Sometimes both are done together (“co-testing”).

How often — and why annual Paps are outdated

Modern US guidelines reflect how slowly this cancer develops. A common framework: start screening at age 21–25; between 21 and 29, a Pap every 3 years; from 30 to 65, either a primary HPV test every 5 years, co-testing every 5 years, or a Pap alone every 3 years. Yearly Pap tests are no longer recommended for most women — not as a cost-cutting measure, but because the cancer grows so slowly that a 3- to 5-year interval catches changes with room to spare while sparing women unnecessary procedures. Always follow your own clinician's plan, especially if you have HIV, a prior abnormal result, or a weakened immune system, all of which call for more frequent checks.

Decoding the scary letters

An abnormal Pap result arrives full of intimidating abbreviations. They are not a cancer diagnosis. Here is what they mean:

ASC-US (atypical squamous cells of undetermined significance) — mildly atypical cells, very common, often nothing. Usually followed by an HPV test; if HPV-negative, you simply return to routine screening.
LSIL (low-grade squamous intraepithelial lesion) — mild changes that frequently reflect an HPV infection the body will clear on its own. Often watched or checked with colposcopy.
HSIL (high-grade squamous intraepithelial lesion) — more significant precancerous changes that warrant a closer look and usually treatment. This is still precancer, not cancer, and treating it is what prevents cancer.

Colposcopy and treating precancer

If results warrant, the next step is colposcopy — an in-office exam with a lighted magnifier and a vinegar wash that makes abnormal areas show up white, allowing a small biopsy. If precancer (CIN 2–3) is confirmed, it is removed with a quick procedure such as a LEEP (loop electrosurgical excision, a thin heated wire that shaves off the abnormal zone) or a cone biopsy. These are usually outpatient and highly effective. One honest caveat worth discussing if you may want children: removing cervical tissue can slightly raise the risk of preterm birth in a future pregnancy, so the amount of tissue taken is kept to what is necessary. Diagnosis of an actual cancer is then confirmed by biopsy and staged with examination and imaging (MRI, CT, or PET).

7. Treatment

Treatment depends almost entirely on the stage, which describes how far the cancer has spread. Doctors use the FIGO staging system (International Federation of Gynecology and Obstetrics), running from Stage I (confined to the cervix) through Stage IV (spread to distant organs). The earlier the stage, the more options — including options that preserve fertility.

Very early disease (Stage I)

For small, early tumors in a woman who hopes to have children, a fertility-sparing trachelectomy — removing the cervix while leaving the uterus — can be both curative and allow future pregnancy. For others, the standard is a radical hysterectomy, which removes the uterus, cervix, and surrounding tissue, often with pelvic lymph nodes.

An important and honest point about how that surgery is done: for years, minimally invasive (keyhole/robotic) radical hysterectomy was assumed to be as safe as open surgery, with faster recovery. Then the randomized LACC trial (Ramirez, 2018) found the opposite — women who had minimally invasive surgery had more cancer recurrences and worse survival than those who had traditional open surgery. As a result, guidelines now recommend open radical hysterectomy as the standard for early cervical cancer. This is a good example of medicine correcting itself when a careful trial overturned a comfortable assumption.

Locally advanced disease (Stage IB3–IVA)

When the cancer is larger or has spread within the pelvis, the standard is chemoradiation — radiation combined with weekly cisplatin chemotherapy that makes the radiation work better. A part that patients are sometimes not told clearly enough: brachytherapy is essential, not optional. Brachytherapy places a radiation source directly inside the cervix to deliver a high, precise dose to the tumor. Studies show that skipping brachytherapy meaningfully lowers cure rates; it is a core part of curative treatment, not an add-on. Newer trials are refining this backbone: the INTERLACE trial (McCormack, 2024) found that adding a short course of chemotherapy before chemoradiation improved survival, while the OUTBACK trial (Mileshkin, 2023) found that adding chemotherapy after chemoradiation did not help — useful, practical knowledge that spares women treatment that wouldn't benefit them.

Advanced, recurrent, or metastatic disease

When cervical cancer has spread to distant organs or returns after treatment, the goal shifts to controlling the disease and extending good-quality life, and the options have genuinely improved:

Bevacizumab — an antibody that starves tumors of new blood vessels; the GOG-240 trial (Tewari, 2014) showed adding it to chemotherapy lengthened survival.
Pembrolizumab (an immunotherapy that releases the brakes on your own immune cells) — the KEYNOTE-826 trial (Colombo, 2021) showed that adding it to chemotherapy improved survival in advanced disease, and it is now a standard option.
Tisotumab vedotin — an “antibody–drug conjugate” that carries a chemotherapy payload directly to cancer cells; the innovaTV 204 study (Coleman, 2021) showed meaningful responses in previously treated recurrent disease.

8. Complications

Complications come both from advanced cancer and from its treatment, and knowing about them helps you ask for support.

From the cancer: bleeding, pelvic pain, blockage of the ureters causing kidney problems, leg swelling (lymphedema), and abnormal connections (fistulas) between the bladder, vagina, or rectum in advanced cases.
From surgery: the usual surgical risks, plus possible bladder-emptying difficulty and, with extensive node removal, leg lymphedema.
From radiation: bowel and bladder irritation, vaginal narrowing and dryness, and reduced fertility. Vaginal dilators and pelvic-floor therapy help, and these should be offered routinely.
Loss of fertility and early menopause when the ovaries are removed or affected by radiation — an enormous personal issue that deserves an early, honest conversation about fertility preservation before treatment begins.
Emotional impact — a cervical cancer diagnosis touches sexuality, fertility, and self-image. Counseling and survivor support are part of good care, not a luxury.

9. Prognosis

The outlook depends heavily on stage at diagnosis — which is the whole argument for screening. In broad terms, US survival figures are:

Localized disease (confined to the cervix): roughly a 92% five-year survival. Caught early, this is a highly curable cancer.
Regional spread (to nearby tissue or lymph nodes): around 60%.
Distant spread (metastatic): roughly 17–19%, though newer immunotherapy and targeted drugs are improving this.
All stages combined: about 67%.

The gap between 92% for early disease and the much lower figures for advanced disease is, in essence, the value of screening expressed as a number. Survival statistics are averages drawn from past patients; your own situation depends on your specific stage, the tumor's features, your overall health, and a treatment landscape that keeps improving.

10. Prevention

This is the most important section on the page, because cervical cancer is one of the few cancers we can genuinely prevent in two complementary ways.

1. The HPV vaccine

The HPV vaccine prevents infection with the high-risk types that cause most cervical cancers, and the evidence is now strong and real-world, not just theoretical. A landmark Swedish study following more than 1.6 million girls and women (Lei, 2020) found that those vaccinated against HPV had a markedly lower rate of actual invasive cervical cancer — with the protection strongest, an ~88% reduction, among those vaccinated before age 17, before exposure to the virus. That is prevention of the cancer itself, measured in real patients over time.

Practical guidance for the US: vaccination is routinely recommended at ages 11–12 (it can start at 9), with catch-up vaccination through age 26 for anyone not adequately vaccinated. For adults aged 27–45, vaccination is a matter of shared decision-making with your clinician — some benefit, depending on prior exposure. The vaccine has an extensive, reassuring safety record across hundreds of millions of doses, with side effects generally limited to a sore arm or brief faintness. Because younger people mount a strong immune response, the schedule is just two doses under age 15.

2. Screening

Vaccination prevents most but not all HPV types, so screening remains essential even for vaccinated women. The Pap and HPV tests find precancer years before cancer could form, allowing simple removal. The single most protective thing an under-screened woman can do is get back on a screening schedule. As the global data make brutally clear, the women who die of cervical cancer are overwhelmingly those who were never screened.

Together: elimination is realistic

Used at population scale, these two tools can drive cervical cancer toward near-elimination. Australia, with high vaccination and organized HPV screening, is projected to reach elimination-level rates within a couple of decades (Hall, 2019). The World Health Organization's global elimination strategy sets the 90–70–90 targets for every country: 90% of girls fully vaccinated by age 15, 70% of women screened with a high-quality test by ages 35 and 45, and 90% of women with cervical disease receiving treatment. Modelling shows that hitting these targets would prevent millions of deaths (Canfell, 2020). Few diseases come with such a clear, achievable roadmap to defeat.

11. Recent Research and Advances

Research is moving on several fronts at once, all aimed at making prevention easier and treatment better:

Single-dose HPV vaccination. A trial in young African women (Barnabas, 2022) found that even a single dose of HPV vaccine gave high protection against persistent infection — a finding with enormous implications for low-resource countries, since one dose is far cheaper and easier to deliver. The WHO now supports single-dose schedules in many settings.
Primary HPV testing and self-collection. Switching from Pap to HPV testing as the first-line screen catches more disease (Ronco, 2014), and self-collected HPV samples — which a woman can take herself — are expanding access for those who avoid pelvic exams.
Better treatment sequencing. The INTERLACE result (adding chemo before chemoradiation helps) and the OUTBACK result (adding it after does not) are reshaping how locally advanced disease is treated.
Immunotherapy and antibody–drug conjugates. Pembrolizumab and tisotumab vedotin have improved outcomes in advanced disease, and many combinations are in trials.
Therapeutic vaccines and HPV-targeted approaches aim to treat existing infections and precancers, not just prevent new ones — an active and promising area.

12. References & Research

Historical Background

The modern story of cervical cancer is one of medicine's great prevention triumphs. In the 1940s, Greek-American pathologist George Papanicolaou introduced the cervical smear — the “Pap test” — which for the first time let doctors find precancerous changes before they ever became cancer; its widespread adoption cut cervical cancer deaths by more than 70% in countries that screened. Decades later, German virologist Harald zur Hausen proposed and proved that human papillomavirus causes cervical cancer, work for which he shared the 2008 Nobel Prize in Physiology or Medicine. That discovery made a vaccine possible, and the first HPV vaccine was approved in 2006. In a single century, cervical cancer went from a common, mysterious killer to a cancer we can vaccinate against, screen for, and credibly aim to eliminate.

Key Research Papers

Lei J, Ploner A, Elfström KM, et al. HPV Vaccination and the Risk of Invasive Cervical Cancer. N Engl J Med. 2020;383(14):1340-1348.
Cohen PA, Jhingran A, Oaknin A, et al. Cervical cancer. The Lancet. 2019;393(10167):169-182.
Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12-19.
Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. The Lancet. 2007;370(9590):890-907.
Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. The Lancet. 2014;383(9916):524-532.
US Preventive Services Task Force (Curry SJ, Krist AH, et al). Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018;320(7):674-686.
Fontham ETH, Wolf AMD, Church TR, et al. Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society. CA Cancer J Clin. 2020;70(5):321-346.
Ramirez PT, Frumovitz M, Pareja R, et al. Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. N Engl J Med. 2018;379(20):1895-1904.
McCormack M, Eminowicz G, Gallardo D, et al. Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): a randomised phase 3 trial. The Lancet. 2024;404(10462):1525-1535.
Mileshkin LR, Moore KN, Barnes EH, et al. Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): a randomised phase 3 trial. The Lancet Oncology. 2023;24(5):468-482.
Tewari KS, Sill MW, Long HJ, et al. Improved Survival with Bevacizumab in Advanced Cervical Cancer. N Engl J Med. 2014;370(8):734-743.
Colombo N, Dubot C, Lorusso D, et al. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. N Engl J Med. 2021;385(20):1856-1867.
Coleman RL, Lorusso D, Gennigens C, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a phase 2 study. The Lancet Oncology. 2021;22(5):609-619.
Barnabas RV, Brown ER, Onono MA, et al. Efficacy of Single-Dose Human Papillomavirus Vaccination among Young African Women. NEJM Evidence. 2022;1(5).
Hall MT, Simms KT, Lew JB, et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study. The Lancet Public Health. 2019;4(1):e19-e27.
Canfell K, Kim JJ, Brisson M, et al. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. The Lancet. 2020;395(10224):591-603.
Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Global Health. 2020;8(2):e191-e203.
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263.

Research Papers

The links below open live PubMed searches so you can read the most current peer-reviewed literature on each aspect of cervical cancer. New studies are indexed continuously, so these searches stay up to date.

Connections

Back to Table of Contents